Business Wire

FERRING-PHARMACEUTICALS

Share
Ferring Pharmaceuticals Announces Changes to Board of Directors

Ferring Pharmaceuticals announced today that Frederik Paulsen is stepping down from his role as Chairman of the Board of Directors* and transitioning to the role of Honorary Chairman. Lars Rebien Sørensen is appointed Chairman of the Board of Directors. Jean-Frédéric Paulsen is also appointed to the Board of Directors. All of these changes are effective immediately.

Mr. Paulsen has been Chairman of Ferring’s Board of Directors since 1988. During Mr Paulsen’s tenure, the company has delivered impressive growth and expanded rapidly into new markets, with a presence in almost 60 countries and revenues of nearly EUR 2 billion today.

“My father Frederik Paulsen and stepmother Eva Paulsen founded Ferring in 1950, and it has been an honour to continue their legacy of pioneering science while driving the global expansion of the company,” said Mr Paulsen. “As Ferring enters its next phase of growth, this is the right moment for me to hand over the reins. With his extraordinary track record, I am confident that Lars will effectively guide Ferring towards its ambitious long-term strategic and financial targets, while keeping alive the pioneering spirit on which the company was built.”

Lars Rebien Sørensen has over three decades of general management experience in the pharmaceutical industry and was President and CEO of Novo Nordisk A/S from 2000 until 2016, spearheading the company’s growth into a highly respected and successful global pharmaceutical company. Today, Mr Sørensen is Chair of the Board of the Novo Nordisk Foundation, Chair of the Board of Novo Holdings A/S, a board member of Thermo Fischer Scientific Inc., as well as Chair of the Advisory Board of Axcel Management A/S.

“I’m excited to take on the role of Chairman of the Board of Directors at Ferring Pharmaceuticals and will seek to build on the company’s strong foundations and continue its impressive track record of growth,” said Mr Sørensen. “I look forward to working with the Board of Directors and the Executive Committee, to bring the company’s long-term strategy to life and help more people around the world build families and live better lives.”

Jean-Frédéric Paulsen is Chairman of Ferring Ventures S.A, in addition to other activities. He previously served as Senior Advisor to four Ministers of Economy and Sustainable Development of Georgia and has worked at Mars Inc, Coca-Cola and Credit Suisse.

After he steps down as Chairman, Frederik Paulsen will transition to Honorary Chairman of Ferring’s Board of Directors, continuing to provide support and ensuring a smooth transition for the Board. Mr Paulsen will also dedicate more time to his passions of polar exploration and climate change science, in addition to his diverse philanthropic activities and the oversight of his other investments.

*Refers to the Board of Directors of Ferring Holding S.A - the parent company of the Ferring Pharmaceuticals group

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com , or connect with us on Twitter , Facebook , Instagram , LinkedIn and YouTube .

# # #

Ferring International Center SA
Ch. de la Vergognausaz, 50
CH-1162 Saint-Prex
Switzerland
www.ferring.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

First in Human Ischemic VT Ablation Successfully Performed in iCMR5.11.2025 16:55:00 CET | Press release

Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR), together with Amsterdam University Medical Centre (Amsterdam UMC), is pleased to announce the successful completion of the first Ischemic Ventricular Tachycardia (VT) ablation ever performed under real-time MRI guidance in an iCMR lab. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105120761/en/ Imricor’s NorthStar® Mapping System The Amsterdam UMC team, shown here, performed the VT ablation procedure following previous experiences performing atrial flutter and premature ventricular complex (PVC) ablation procedures guided by real-time MRI and Imricor’s NorthStar® Mapping System. Regarding the VT procedure, Dr. Kemme, stated: “This procedure is part of an international research programme. The MRI imaging shows us precisely where the myocardial infarction took place; therefore, we can send the catheter to the exact spot. This information can make ablation possi

SIS Medical AG Welcomes the Results of the VICTORY Trial Demonstrating Non-inferiority of OPN NC to Intravascular Lithotrispy (IVL) for Lesion Preparation and Stent Expansion in Severely Calcified Lesions5.11.2025 16:12:00 CET | Press release

SIS Medical AG, a Swiss manufacturer of the Super-High-Pressure PTCA balloon catheter (OPN NC), is pleased to announce that the results of the investigator-initiated VICTORY trial were presented during the late-breaking clinical session at TCT 2025 by the Cardiovascular Research Foundation (CRF). The randomized, multi-center clinical study was designed to compare the safety and efficacy between the OPN and IVL devices for lesion preparation and optimized stent expansion in highly complex calcified coronary lesions, deploying a drug-eluting stent (DES). Coronary artery calcium affects approximately one-third of patients undergoing PCI and is a key contributor to procedural and stent failure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105812157/en/ "With a similar safety profile, OPN can be a feasible and faster alternative to IVL." Dr. M. Bossard, Senior Physician at Luzerner Kantonsspital, Switzerland A total of 282 p

Doha Debates Explores the Role of Ancient Wisdom in Today’s World5.11.2025 16:06:00 CET | Press release

Experts and students debate whether ancient wisdom holds answers for modern societies As the world grapples with questions of meaning and moral direction, Doha Debates takes on a fundamental question: Should ancient wisdom guide today’s societies? This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105183709/en/ Guest speakers and participating students gather on the Doha Debates stage to discuss a fundamental question “Should ancient wisdom guide today’s societies?” — part of the show’s exploration of timeless questions shaping our world today. (Photo: AETOSWire) In this episode of the new flagship season, moderated by Dareen Abughaida, students from across Qatar join three global thinkers to wrestle with a timeless dilemma: whether the answers to our most pressing problems lie in tradition or in bold new ideas. Wael Hallaq, Avalon Foundation Professor in the Humanities at Columbia University, critiques what he calls the “mor

Versa Delivers Proven Firewall Performance and Security Effectiveness Validated by Independent Testing5.11.2025 15:30:00 CET | Press release

Versa One of Only Three Recommended Products, Maintaining Position as Performance Leader by Delivering Fastest Throughput While Achieving a 99.43% Security Effectiveness Score Versa, the global leader in unified networking and security, today announced that its Next-Generation Firewall received CyberRatings.org’s highest “Recommended” rating for the ninth consecutive year. In the newly published Q3 2025 Enterprise Firewall report, based on independent testing by NSS Labs, Versa delivered 100% scores in critical categories like malware and exploit evasion resistance, and achieved a leading 7,626 Mbps rated throughput, over twice as fast as competing solutions. Selecting cybersecurity solutions requires unbiased, real-world performance testing and evaluation. CyberRatings.org provides IT and security leaders with data-driven results to guide investment decisions. In this latest assessment, Versa ranked among the top three vendors for Security Effectiveness and delivered more than twice t

Its Global Vision on Show, TVS Motor Company Makes a Stellar Debut at EICMA5.11.2025 15:16:00 CET | Press release

Six new products - a resurgent “new Norton”, connected technology, AR based Heads-Up Display Helmets, new range of accessories and a roadmap for Europe - underline TVSM’s presence at the world’s largest 2-wheeler exhibition. TVS Motor Company (TVSM) - a global leader in two and three-wheeler manufacturing - has taken centerstage at EICMA 2025, making a landmark debut at the world’s largest motorcycle exhibition. With a show floor commanding presence, TVS unveiled 6 new products across ICE and thermal powertrains, advanced ride assist gear including AR based Heads-Up display helmets, a stunning new range of accessories, connected technology that enhances rider-machine connect and its roadmap for expansion in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105242034/en/ TVS top leadership team posing with the global showcases at EICMA. From L to R: TVS M1-S, TVS X, TVS eFX three O, TVS RTX 300 and RTX 300 BTO, TVS Ta

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye